Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-003320-16
    Sponsor's Protocol Code Number:CEL-03
    National Competent Authority:Czechia - SUKL
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-01-11
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedCzechia - SUKL
    A.2EudraCT number2020-003320-16
    A.3Full title of the trial
    A Phase 3 prospective, blinded, randomized, placebo controlled,
    international multicenter study to assess the safety and efficacy of a single
    subcutaneous injection of zalunfiban in subjects with ST-elevation
    myocardial infarction in the pre-hospital setting
    Prospektivní, zaslepené, randomizované, placebem kontrolované mezinárodní multicentrické klinické hodnocení fáze 3 zkoumající bezpečnost a účinnost jedné subkutánní injekce zalunfibanu u pacientů s infarktem myokardu s elevací ST v přednemocniční péči
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to assess the effects of a platelet inhibitor (zalunfiban). This
    platelet inhibitor is given by a single subcutaneous injection.
    Targeted patients are patients with an acute myocardial infarction. The
    medication will be given in the ambulance. Subsequently a coronary
    angiography will be perormed and if needed the patient will be treated
    with primary coronary angioplasty
    Studie hodnotící účinky inhibitoru krevních destiček (zalunfiban). Tento inhibitor krevních destiček se podává jedenkrát subkutánní injekcí. Cílovými pacienty jsou pacienti s akutním infarktem myokardu. Lék bude podán v sanitním voze. Následně bude provedena koronární angiografie a v případě potřeby bude pacient léčen primární koronární angioplastikou
    A.3.2Name or abbreviated title of the trial where available
    CELEBRATE
    A.4.1Sponsor's protocol code numberCEL-03
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCeleCor Therapeutics, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCeleCor Therapeutics, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationDiagram BV
    B.5.2Functional name of contact pointS. Postma
    B.5.3 Address:
    B.5.3.1Street AddressDokter Stolteweg 96
    B.5.3.2Town/ cityZwolle
    B.5.3.3Post code8025 AZ
    B.5.3.4CountryNetherlands
    B.5.4Telephone number003138426 2999
    B.5.6E-mails.postma@diagram-zwolle.nl
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namezalunfiban
    D.3.2Product code 140962
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNzalunfiban
    D.3.9.2Current sponsor code RUC-4
    D.3.9.3Other descriptive nameGLYCOPROTEIN IIB/IIIA
    D.3.9.4EV Substance CodeSUB194833
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number18
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Subjects with documented STEMI, presenting with persistent ischemic chest pain (>10 minutes) and new ≥2 mm ST-segment elevation in 2 adjacent ECG leads, in whom the total duration of symptoms to diagnostic ECG is anticipated to be within 4 hours.
    E.1.1.1Medical condition in easily understood language
    Patients with an Acute Myocardial Infarction presenting with specific abnormalities on their electrocardiogram. These patients are scheduled to undergo PCI (dotter treatment).
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLGT
    E.1.2Classification code 10028593
    E.1.2Term Myocardial disorders
    E.1.2System Organ Class 10007541 - Cardiac disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10000891
    E.1.2Term Acute myocardial infarction
    E.1.2System Organ Class 10007541 - Cardiac disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10028600
    E.1.2Term Myocardial ischaemia
    E.1.2System Organ Class 10007541 - Cardiac disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level PT
    E.1.2Classification code 10081099
    E.1.2Term Acute cardiac event
    E.1.2System Organ Class 10007541 - Cardiac disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.1
    E.1.2Level LLT
    E.1.2Classification code 10062084
    E.1.2Term Platelet aggregation
    E.1.2System Organ Class 100000004848
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10050661
    E.1.2Term Platelet aggregation inhibition
    E.1.2System Organ Class 10005329 - Blood and lymphatic system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Efficacy:
    - To assess the clinical outcome at 30-day follow-up after administration of a single subcutaneous injection of zalunfiban versus
    placebo in STEMI subjects in the pre-hospital setting.

    Safety:
    - To assess bleeding events (according to Global Use of Strategies to Open Occluded Coronary Arteries [GUSTO] severe or life threatening criterion for safety assessment and, for information only, according to the Bleeding Academic Research Consortium [BARC] Types 3C and 5 criteria for information only) after a single subcutaneous injection of zalunfiban versus placebo at 30 days follow-up.
    E.2.2Secondary objectives of the trial
    To assess after a single s.c. injection of zalunfiban vs placebo:
    Efficacy:
    -Restoration of the culprit coronary artery blood flow of the Culprit
    before intended PCI (or post-CAG in case no PCI performed)
    -Resolution of ST-segment deviation post-PCI/CAG
    - Blinded bail-out use of IV αIIbβ3 receptor antagonists or IV P2Y12 antagonist at 24 hours post-PCI/angiography

    Safety:
    -Safety throughout study
    -Platelet count pre-PCI/CAG, post-PCI/CAG, 6hr post-PCI/CAG, 24hr
    post-PCI/CAG and at discharge/72hr post-PCI/s (whichever occurs first)
    - Bleeding events at 30 day FU:
    - According to ISTH Major
    - According to GUSTO mild and moderate criteria, BARC Types 2, 3, and 5 criteria, ISTH minor and/or major bleeding, and TIMI minor and major criteria)
    -The injection site reactions of a single s.c. injection of zalunfiban versus placebo at baseline, 1hr post-PCI/CAG, hospital discharge/72hr post-
    PCI/CAG, and at 30-day FU
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Planned transport to participating clinical site
    - Males aged ≥18 years or post-menopausal or surgically sterile females ≥50 years or ≥55 years (for Czech Republic study sites only).
    - Weight (by history) between 52 and 130 kg (115 and 287 lb).
    - Subjects with documented STEMI, presenting with persistent ischemic chest pain (>10 minutes) and new ≥2 mm ST-segment elevation in 2 adjacent ECG leads, in whom the total duration of symptoms to diagnostic ECG is 4 hours maximum.
    - Enrollment by EFIC process, verbal witnessed/short written informed consent, or written informed consent will be obtained in the acute phase by (para)medics [Romania and other select sites with the sponsor's approval: clinical site personnel, if greater than 30 minutes of delay is anticipated for
    door-to-balloon time]. Subject is willing and able to give informed consent. Written informed consent will be obtained as soon as the subject's clinical condition allows it.
    E.4Principal exclusion criteria
    - Cardio Pulmonary Resuscitation (CPR) for current Out of Hospital Cardiac Arrest (OHCA).
    - Cardiogenic shock presenting with systolic blood pressure <90 mmHg confirmed on repeat testing and heart rate >100 beats per minute (bpm).
    - Current known active coronavirus disease 2019 (COVID-19) infection (criteria according to local guidelines.
    - Currently treated with renal dialysis.
    - Current treatment with oral anticoagulation (Vitamin K* antagonists or direct oral anticoagulants **) and thrombolytic agents***. For
    example..
    * acenocoumarol or phenprocoumon, fluindione, and Coumadin (warfarin)
    ** dabigatran, apixaban, edoxaban, rivaroxaban and betrixaban
    *** tenecteplase, alteplase, reteplase, streptokinase, and urokinase
    - Major surgery, or trauma or bleeding leading to hospitalization, within the past month.
    - Known history of ischemic or hemorrhagic stroke.
    - Known severe anemia (regular blood transfusion needed).
    - Previously enrolled in this study.
    - Participation in another clinical study with an investigational product or device within the past month.
    - Life expectancy less than one year.
    E.5 End points
    E.5.1Primary end point(s)
    Efficacy:
    To assess after a single subcutaneous injection of zalunfiban versus
    placebo:
    Clinical outcome as assessed by a 7-point scale. The 7 outcomes,
    ranking from worst to best, are:
    a. Death (all cause) at 30-day follow-up
    b. Stroke at 30-day follow-up
    c. Recurrent MI (Types 1 to 4 MI) at 30-day follow-up
    d. Acute stent thrombosis at 24 hours post-PCI/angiography
    e. New onset HF or rehospitalization for HF at 30-day follow-up
    f. MI with hs-cTnT levels ≥10x ULN at 24 hours post-PCI/angiography
    g. None of the above

    Safety:
    To assess after a single subcutaneous injection of zalunfiban versus
    placebo:
    - Subject incidence of bleeding events (according to GUSTO
    severe or life-threatening criterion for safety assessment and, for
    information only, according to the BARC Types 3C and 5 criteria)
    at 30 days follow-up
    E.5.1.1Timepoint(s) of evaluation of this end point
    see primary end points (E.5.1)
    E.5.2Secondary end point(s)
    Efficacy:
    To assess after a single subcutaneous injection of zalunfiban versus
    placebo:
    - As assessed by an independent Core Laboratory: Corrected TIMI
    Frame Count of the Infarct-Related Artery (Culprit) before
    PCI/angiography
    - As assessed by an independent Core Laboratory: ST-segment
    deviation resolution 1-hour post-PCI/angiography
    - Blinded bail-out use of IV αIIbβ3 receptor antagonists or IV P2Y12 antagonists at 24 hours post-PCI/angiography

    Safety
    To assess after a single subcutaneous injection of zalunfiban versus
    placebo:
    - Recording of AEs and SAEs: AEs up to 30-day follow-up; SAEs up to resolution/stabilization, the SAEs mortality and hospitalization for heart failure and atrial fibrillation up to 12-months follow-up
    - Platelet count before PCI/angiography, at the end of the PCI/angiography, 6 and 24 hours post-PCI/angiography, and at hospital discharge/72-hours post-PCI/angiography (whichever occurs first)
    - Subject incidence of bleeding events (according to ISTH Major and, for information only, TIMI Major) at 30 days follow-up
    - Subject incidence of bleeding events according to GUSTO mild and moderate criteria, BARC Types 2, 3, and 5 criteria, ISTH minor and/or major bleeding, and TIMI minor and major criteria at 30 days follow-up
    - Subject incidence of injection site reactions at baseline, 1-hour post-PCI/angiography, hospital discharge/72-hours post- PCI/angiography, and at 30 days follow-up
    E.5.2.1Timepoint(s) of evaluation of this end point
    see secondary end points (E.5.2)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA48
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    United States
    Czechia
    France
    Hungary
    Netherlands
    Romania
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    A subject is considered to have completed the study if he/she has completed the 30-day FU visit. After Day 30 FU visit, subjects will continue to long-term assessment at Month 12.
    The end of the study is met when all patients have completed all assessments, all data have been cleaned and study site has been closed.
    A possible reason for early study termination includes that the SRC makes a decision for the early termination of the study per recommendation.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1000
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 1499
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state130
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 2399
    F.4.2.2In the whole clinical trial 2499
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-04-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-02-17
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 05 13:10:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA